Avid Bioservices (CDMO) Financials

$12.50 +0.02 (+0.12%)

Closing price 02/5/2025

Extended Trading

$12.50 0.00 (0.00%)

As of 02/5/2025 04:23 PM Eastern

Annual Income Statements for Avid Bioservices

This table shows Avid Bioservices' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-36	-54	-60	-33	-26	-8.90	-15	3.32	128	0.26	-141
Consolidated Net Income / (Loss)	-35	-50	-56	-28	-22	-4.22	-10	11	128	0.26	-141
Net Income / (Loss) Continuing Operations	-35	-50	3.60	1.39	-21	-5.06	-10	11	128	0.26	-141
Total Pre-Tax Income	-35	-50	3.60	1.39	-21	-5.34	-10	11	13	1.59	-27
Total Operating Income	-36	-50	3.49	1.29	-21	-5.62	-11	12	15	3.60	-19
Total Gross Profit	22	11	21	19	-2.92	7.22	3.93	29	37	31	7.32
Total Revenue	22	27	44	58	54	54	60	96	120	149	140
Operating Revenue	22	27	44	58	54	54	60	96	120	149	140
Total Cost of Revenue	0.00	16	23	38	57	46	56	67	83	118	133
Operating Cost of Revenue	-	16	23	38	57	46	56	67	83	118	133
Total Operating Expenses	58	62	18	18	18	13	15	17	21	28	26
Selling, General & Admin Expense	17	19	18	18	16	13	15	17	21	28	26
Total Other Income / (Expense), net	0.35	0.14	0.12	0.10	0.08	0.28	0.47	-1.03	-2.76	-2.01	-8.25
Interest Expense	-	-	-	-	-	0.01	0.01	1.16	2.68	3.01	4.34
Other Income / (Expense), net	-	-	-	-	-	-	0.48	0.13	-0.08	1.00	-3.91
Income Tax Expense	-	-	-	0.00	0.00	-0.28	0.00	0.00	-115	1.33	114
Basic Earnings per Share	($0.22)	($2.07)	($1.95)	($0.88)	($0.56)	($0.16)	($0.27)	$0.06	$2.08	$0.00	($2.23)
Weighted Average Basic Shares Outstanding	161.58M	26.08M	30.90M	37.11M	47.06M	55.98M	56.33M	58.22M	61.48M	62.27M	63.20M
Diluted Earnings per Share	($0.22)	($2.07)	($1.95)	($0.88)	($0.56)	($0.16)	($0.27)	$0.06	$1.84	$0.00	($2.23)
Weighted Average Diluted Shares Outstanding	161.58M	26.08M	30.90M	37.11M	47.06M	55.98M	56.33M	59.43M	70.47M	63.78M	63.20M
Weighted Average Basic & Diluted Shares Outstanding	161.58M	26.08M	30.90M	37.11M	47.06M	55.98M	56.33M	61.10M	61.83M	62.73M	63.58M

This table shows Avid Bioservices' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Net Income / (Loss) Attributable to Common Shareholders	120	1.36	-0.52	-0.25	-0.34	-2.12	-9.52	-6.01	-123	-5.53	-17
Consolidated Net Income / (Loss)	120	1.36	-0.52	-0.25	-0.34	-2.12	-9.52	-6.01	-123	-5.53	-17
Net Income / (Loss) Continuing Operations	120	1.36	-0.52	-0.25	-0.34	-2.12	-9.52	-6.01	-123	-5.53	-17
Total Pre-Tax Income	7.35	1.94	-3.42	2.51	0.55	-2.73	-12	-7.06	-5.23	-5.53	-17
Total Operating Income	7.91	2.74	-2.68	2.72	0.83	-2.16	-11	-4.00	-1.29	-2.46	-13
Total Gross Profit	12	9.12	4.15	9.83	8.39	4.10	-4.67	2.38	5.50	5.71	-2.05
Total Revenue	23	37	35	38	40	38	25	34	43	40	33
Operating Revenue	23	37	35	38	40	38	25	34	43	40	33
Total Cost of Revenue	11	28	31	28	31	34	30	31	37	34	36
Operating Cost of Revenue	11	28	31	28	31	34	30	31	37	34	36
Total Operating Expenses	4.12	6.38	6.83	7.11	7.56	6.26	6.56	6.38	6.79	8.17	11
Selling, General & Admin Expense	4.12	6.38	6.83	7.11	7.56	6.26	6.56	6.38	6.79	8.17	11
Total Other Income / (Expense), net	-0.56	-0.79	-0.73	-0.20	-0.28	-0.57	-0.69	-3.06	-3.94	-3.08	-4.78
Interest Expense	0.56	0.84	0.88	0.64	0.66	0.83	0.83	0.88	1.81	2.45	3.28
Other Income / (Expense), net	0.00	0.05	0.15	0.43	0.38	0.26	0.14	-2.18	-2.13	-0.62	-1.50
Income Tax Expense	-113	0.58	-2.90	2.76	0.88	-0.61	-2.39	-1.05	118	0.00	0.00
Basic Earnings per Share	$1.96	$0.02	($0.01)	$0.00	($0.01)	($0.03)	($0.15)	($0.09)	($1.96)	($0.09)	($0.27)
Weighted Average Basic Shares Outstanding	61.48M	61.91M	62.20M	62.39M	62.27M	62.84M	63.15M	63.32M	63.20M	63.64M	63.84M
Diluted Earnings per Share	$1.72	$0.02	($0.01)	$0.00	($0.01)	($0.03)	($0.15)	($0.09)	($1.96)	($0.09)	($0.27)
Weighted Average Diluted Shares Outstanding	70.47M	63.33M	62.20M	69.16M	63.78M	62.84M	63.15M	63.32M	63.20M	63.64M	63.84M
Weighted Average Basic & Diluted Shares Outstanding	61.83M	62.17M	-	62.55M	62.73M	63.11M	63.24M	63.48M	63.58M	63.80M	63.96M

This table details how cash moves in and out of Avid Bioservices' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	42	-9.49	-6.59	-14	-4.53	-9.91	3.11	134	-44	-88	-0.79
Net Cash From Operating Activities	-28	-36	-40	-39	-26	-12	5.83	31	9.47	-13	11
Net Cash From Continuing Operating Activities	-28	-36	-40	-36	-23	-7.05	5.83	31	9.47	-13	11
Net Income / (Loss) Continuing Operations	-35	-50	-56	-28	-22	-4.22	-10	11	128	0.26	-141
Consolidated Net Income / (Loss)	-35	-50	-56	-28	-22	-4.22	-10	11	128	0.26	-141
Depreciation Expense	0.99	1.04	1.54	2.46	2.56	2.75	3.09	3.45	4.48	7.21	11
Amortization Expense	-	-	-	-	-	0.00	0.00	0.92	1.03	1.05	1.50
Non-Cash Adjustments To Reconcile Net Income	6.21	6.70	4.91	15	-22	-6.09	18	23	12	-9.57	12
Changes in Operating Assets and Liabilities, net	-0.09	6.59	9.61	-25	18	0.51	-4.81	-7.09	-135	-12	127
Net Cash From Investing Activities	-2.52	-8.45	-8.79	-3.06	-0.79	4.54	-3.81	-9.86	-56	-78	-32
Net Cash From Continuing Investing Activities	-2.52	-8.45	-8.79	-3.06	-0.79	4.54	-3.81	-9.86	-56	-78	-32
Purchase of Property, Plant & Equipment	-0.76	-9.05	-8.88	-3.63	-3.79	-1.50	-3.81	-9.86	-56	-78	-32
Net Cash From Financing Activities	73	35	42	28	22	-2.86	1.10	112	3.20	2.90	20
Net Cash From Continuing Financing Activities	73	35	42	28	22	-2.86	1.10	112	3.20	2.90	20
Repayment of Debt	-0.03	-0.01	0.00	-0.14	-0.18	-0.07	4.38	-4.47	-0.16	-0.51	-143
Issuance of Debt	-	-	-	-	0.00	0.00	0.00	138	0.00	0.00	154
Issuance of Common Equity	54	20	46	31	26	1.54	1.12	36	3.36	3.41	1.40
Other Financing Activities, net	0.94	0.30	0.14	0.03	0.75	0.00	-0.08	-13	0.00	0.00	7.41
Cash Interest Paid	0.00	0.00	0.00	0.01	0.00	0.01	0.01	0.01	1.67	1.12	2.56
Cash Income Taxes Paid	-	-	-	-	-	-	0.00	0.00	0.06	0.26	0.02

This table details how cash moves in and out of Avid Bioservices' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Net Change in Cash & Equivalents	-24	-11	-38	-17	-21	-14	6.18	-0.72	7.40	-4.73	0.03
Net Cash From Operating Activities	0.61	-5.09	-3.84	-6.94	3.15	-0.24	6.24	3.69	1.26	-3.68	3.99
Net Cash From Continuing Operating Activities	0.61	-5.09	-3.84	-6.94	3.15	-0.24	6.24	3.69	1.26	-3.68	3.99
Net Income / (Loss) Continuing Operations	116	1.36	-0.52	-0.25	-0.34	-2.12	-9.52	-6.01	-123	-5.53	-17
Consolidated Net Income / (Loss)	116	1.36	-0.52	-0.25	-0.34	-2.12	-9.52	-6.01	-123	-5.53	-17
Depreciation Expense	1.42	1.59	1.82	1.92	1.88	2.65	2.78	2.82	2.86	2.82	3.97
Amortization Expense	0.26	0.26	0.26	0.26	0.26	0.34	0.30	0.28	0.59	0.31	0.28
Non-Cash Adjustments To Reconcile Net Income	-5.19	-0.80	-0.96	-12	3.99	-6.79	19	7.89	-8.72	-1.41	20
Changes in Operating Assets and Liabilities, net	-111	-7.50	-4.44	2.93	-2.66	5.69	-6.53	-1.29	130	0.13	-2.74
Net Cash From Investing Activities	-25	-6.87	-34	-11	-25	-14	-7.47	-4.49	-5.69	-1.31	-3.45
Net Cash From Continuing Investing Activities	-25	-6.87	-34	-11	-25	-14	-7.47	-4.49	-5.69	-1.31	-3.45
Purchase of Property, Plant & Equipment	-25	-6.87	-34	-11	-25	-14	-7.47	-4.49	-5.69	-1.31	-3.45
Net Cash From Financing Activities	0.16	0.93	0.40	0.87	0.70	0.75	7.40	0.09	12	0.27	-0.51
Net Cash From Continuing Financing Activities	0.16	0.93	0.40	0.87	0.70	0.75	7.40	0.09	12	0.27	-0.51
Repayment of Debt	-0.16	-0.08	-0.17	-0.13	-0.13	-0.13	-0.13	-0.30	-142	-0.35	-0.62
Issuance of Common Equity	0.33	1.01	0.57	1.00	0.83	0.88	0.12	0.38	0.01	0.62	0.11
Cash Interest Paid	0.76	0.02	0.73	-0.26	0.63	0.03	0.57	0.01	1.96	0.17	4.28
Cash Income Taxes Paid	0.06	0.04	0.18	-	0.04	0.01	0.00	-	0.00	0.03	0.00

This table presents Avid Bioservices' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	91	97	109	118	96	78	108	266	430	452	337
Total Current Assets	86	81	82	90	68	51	60	208	180	112	104
Cash & Equivalents	77	68	61	47	42	32	36	170	126	39	38
Accounts Receivable	1.33	3.81	2.86	7.74	3.75	7.37	8.61	19	21	18	17
Inventories, net	5.53	7.35	16	33	16	6.56	11	12	26	44	30
Prepaid Expenses	1.42	1.36	1.35	0.81	0.68	0.71	0.71	1.06	1.88	2.09	6.51
Other Current Assets	-	-	-	-	0.00	4.33	3.30	6.11	5.37	9.61	12
Plant, Property, & Equipment, net	2.45	15	24	26	26	26	27	37	93	178	187
Total Noncurrent Assets	2.33	1.82	2.93	2.19	1.45	1.45	21	20	157	161	46
Other Noncurrent Operating Assets	2.33	1.82	2.33	1.04	1.45	1.45	21	20	41	47	46
Total Liabilities & Shareholders' Equity	91	97	109	118	96	78	108	266	430	452	337
Total Liabilities	23	38	59	65	40	25	66	188	255	262	276
Total Current Liabilities	22	37	58	63	38	23	44	71	76	215	71
Accounts Payable	2.43	10	8.43	3.00	1.91	4.35	5.93	9.26	9.50	25	21
Current Deferred Revenue	11	18	34	46	-	-	-	-	54	37	40
Current Employee Benefit Liabilities	3.84	4.61	5.82	5.06	2.56	3.54	3.02	8.79	8.42	8.78	5.44
Other Current Liabilities	0.50	0.44	1.49	0.64	29	15	31	53	4.04	3.80	4.58
Total Noncurrent Liabilities	0.64	1.10	1.40	1.60	2.16	2.17	21	117	180	47	205
Long-Term Debt	-	-	-	-	-	-	0.00	97	140	0.00	154
Other Noncurrent Operating Liabilities	-	-	-	-	-	0.09	21	20	40	47	52
Commitments & Contingencies	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	68	59	50	54	56	53	42	78	175	189	61
Total Preferred & Common Equity	68	59	50	54	56	53	42	78	175	189	61
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	68	59	50	54	56	53	42	78	175	189	61
Common Stock	471	513	559	591	615	614	613	638	606	620	633
Retained Earnings	-403	-454	-509	-537	-559	-561	-571	-560	-431	-431	-572

This table presents Avid Bioservices' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025
Total Assets	314	451	450	443	455	455	335	323
Total Current Assets	203	181	132	98	104	104	104	97
Cash & Equivalents	150	115	60	25	31	31	33	33
Accounts Receivable	28	26	15	16	13	19	21	18
Inventories, net	21	30	45	41	39	35	29	28
Prepaid Expenses	1.13	2.12	2.11	1.89	9.97	7.58	5.87	4.80
Other Current Assets	3.34	7.08	10	14	11	12	14	12
Plant, Property, & Equipment, net	69	115	164	183	188	188	186	182
Total Noncurrent Assets	41	156	154	162	163	164	45	45
Other Noncurrent Operating Assets	41	41	39	47	47	46	45	45
Total Liabilities & Shareholders' Equity	314	451	450	443	455	455	335	323
Total Liabilities	258	272	265	253	272	275	276	279
Total Current Liabilities	77	93	87	206	219	223	71	74
Accounts Payable	6.46	30	36	23	23	20	20	9.25
Current Deferred Revenue	-	-	-	33	46	53	38	52
Current Employee Benefit Liabilities	7.74	5.30	8.40	4.67	4.24	4.11	5.61	8.22
Other Current Liabilities	63	58	43	4.56	4.66	4.90	7.82	5.01
Total Noncurrent Liabilities	180	179	178	47	53	52	205	205
Long-Term Debt	139	140	140	-	-	-	154	154
Other Noncurrent Operating Liabilities	41	39	37	45	53	52	51	50
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	57	179	185	190	183	180	59	45
Total Preferred & Common Equity	57	179	185	190	183	180	59	45
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	57	179	185	190	183	180	59	45
Common Stock	604	609	616	624	626	629	636	640
Retained Earnings	-547	-430	-431	-433	-443	-449	-577	-595

This table displays calculated financial ratios and metrics derived from Avid Bioservices' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.31%	19.55%	65.63%	29.92%	-6.96%	-0.03%	11.38%	60.58%	24.75%	24.81%	-6.27%
EBITDA Growth	-27.34%	-42.45%	110.15%	-25.23%	-581.38%	84.09%	-156.15%	327.30%	24.52%	-38.33%	-177.60%
EBIT Growth	-25.94%	-41.43%	106.91%	-62.95%	-1,697.37%	72.76%	-86.02%	218.34%	23.96%	-70.00%	-590.77%
NOPAT Growth	-25.94%	-41.43%	109.86%	-62.95%	-1,218.16%	72.76%	-94.59%	259.87%	1,170.22%	-99.62%	-2,328.96%
Net Income Growth	-18.74%	-42.41%	-10.51%	49.40%	22.54%	80.68%	-148.30%	207.13%	1,038.71%	-99.80%	-54,444.79%
EPS Growth	12.00%	-840.91%	5.80%	54.87%	36.36%	71.43%	-68.75%	122.22%	2,966.67%	-100.00%	0.00%
Operating Cash Flow Growth	-35.02%	-27.48%	-9.92%	1.07%	33.64%	55.39%	150.25%	435.13%	-69.65%	-234.41%	186.09%
Free Cash Flow Firm Growth	-57.19%	-35.75%	117.86%	-465.01%	38.33%	20.02%	126.19%	474.06%	-256.14%	-276.24%	198.69%
Invested Capital Growth	14.44%	8.43%	-33.15%	208.31%	0.72%	59.08%	-51.67%	-52.36%	3,832.64%	55.07%	-39.34%
Revenue Q/Q Growth	11.00%	11.83%	25.97%	-0.95%	-16.97%	23.25%	-7.02%	18.63%	-4.03%	13.04%	2.32%
EBITDA Q/Q Growth	-6.43%	-3.45%	109.06%	-88.84%	-395.99%	68.80%	-143.78%	117.95%	28.24%	-32.66%	-50.05%
EBIT Q/Q Growth	-6.14%	-3.36%	106.16%	-95.86%	-681.52%	52.52%	-73.20%	185.95%	44.67%	-59.28%	-25.76%
NOPAT Q/Q Growth	-6.14%	-3.36%	108.80%	-95.86%	-507.06%	52.52%	-81.19%	182.88%	1,366.56%	-99.62%	-12.84%
Net Income Q/Q Growth	-5.36%	-3.89%	0.45%	19.02%	27.54%	-175.31%	-95.19%	151.79%	1,260.09%	-99.79%	-682.66%
EPS Q/Q Growth	0.00%	-613.79%	5.80%	64.66%	0.00%	0.00%	0.00%	0.00%	1,740.00%	-100.00%	-696.43%
Operating Cash Flow Q/Q Growth	-6.78%	10.22%	-8.82%	-17.86%	34.45%	23.38%	-30.86%	90.49%	-64.57%	16.60%	-14.70%
Free Cash Flow Firm Q/Q Growth	-9.67%	1.87%	117.21%	-191.53%	-32.23%	42.52%	-18.91%	180.09%	-30.95%	-55.24%	376.75%
Invested Capital Q/Q Growth	-20.79%	-64.70%	-58.39%	711.64%	4.76%	-15.00%	-38.91%	-67.05%	308.41%	9.43%	-39.34%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	41.78%	48.22%	33.61%	-5.45%	13.48%	6.59%	30.57%	30.64%	21.09%	5.23%
EBITDA Margin	-154.99%	-184.68%	11.32%	6.52%	-33.71%	-5.37%	-12.34%	17.47%	17.43%	8.61%	-7.13%
Operating Margin	-159.39%	-188.56%	7.86%	2.24%	-38.49%	-10.49%	-18.32%	12.77%	12.90%	2.41%	-13.35%
EBIT Margin	-159.39%	-188.56%	7.86%	2.24%	-38.49%	-10.49%	-17.52%	12.91%	12.83%	3.08%	-16.15%
Profit (Net Income) Margin	-157.86%	-188.04%	-125.46%	-48.86%	-40.68%	-7.86%	-17.53%	11.70%	106.75%	0.17%	-100.60%
Tax Burden Percent	100.01%	100.00%	-1,547.18%	-2,021.46%	106.08%	78.93%	100.00%	100.00%	1,008.39%	16.29%	522.72%
Interest Burden Percent	99.02%	99.72%	103.15%	107.82%	99.64%	94.98%	100.08%	90.59%	82.53%	34.54%	119.20%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-908.39%	83.71%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	260.48%	-111.33%	-23.33%	-49.84%	165.64%	161.69%	0.25%	-5.60%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	317.86%	-93.66%	-22.58%	-41.10%	167.60%	254.65%	-0.33%	-123.11%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	-314.82%	71.42%	15.58%	27.80%	-146.89%	-60.47%	-0.10%	-106.98%
Return on Equity (ROE)	-77.33%	-79.47%	-102.01%	-54.33%	-39.91%	-7.75%	-22.04%	18.74%	101.22%	0.14%	-112.58%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-182.34%	-112.05%	-68.94%	19.82%	236.57%	-28.39%	-42.94%	43.38%
Operating Return on Assets (OROA)	-52.66%	-53.72%	3.38%	1.14%	-19.30%	-6.46%	-11.24%	6.63%	4.41%	1.04%	-5.73%
Return on Assets (ROA)	-52.16%	-53.57%	-53.90%	-24.79%	-20.40%	-4.84%	-11.25%	6.01%	36.72%	0.06%	-35.72%
Return on Common Equity (ROCE)	-77.33%	-79.47%	-102.01%	-54.33%	-39.91%	-7.75%	-22.04%	18.74%	101.22%	0.14%	-112.58%
Return on Equity Simple (ROE_SIMPLE)	-52.23%	-85.30%	-111.14%	-52.55%	-39.13%	-7.94%	-24.98%	14.42%	73.15%	0.14%	-231.16%
Net Operating Profit after Tax (NOPAT)	-25	-35	3.49	1.29	-14	-3.94	-7.66	12	156	0.59	-13
NOPAT Margin	-111.58%	-131.99%	7.86%	2.24%	-26.94%	-7.34%	-12.83%	12.77%	130.03%	0.39%	-9.34%
Net Nonoperating Expense Percent (NNEP)	-18.40%	-20.63%	-90.97%	-57.37%	-17.67%	-0.74%	-8.74%	-1.97%	-92.95%	0.57%	117.52%
Cost of Revenue to Revenue	0.00%	58.22%	51.78%	66.39%	105.45%	86.52%	93.41%	69.43%	69.36%	78.91%	94.77%
SG&A Expenses to Revenue	77.13%	69.80%	40.40%	31.37%	30.69%	23.97%	24.32%	17.80%	17.75%	18.68%	18.58%
R&D to Revenue	123.76%	160.55%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	259.42%	230.34%	40.40%	31.37%	33.04%	23.97%	24.91%	17.80%	17.75%	18.68%	18.58%
Earnings before Interest and Taxes (EBIT)	-36	-50	3.49	1.29	-21	-5.62	-10	12	15	4.60	-23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-35	-49	5.02	3.76	-18	-2.88	-7.37	17	21	13	-9.98
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	3.66	5.06	8.22	16.75	4.76	5.97	7.95
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	3.66	5.06	8.22	16.75	4.76	5.97	7.95
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	3.80	5.01	5.77	13.58	6.95	7.56	3.46
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	392.42	6.51	4,358.97	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.25%	15.36%	0.02%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	12.41	11.40	31.23	257.67	4.50	4.23	3.40
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	3.01	4.41	5.24	12.82	7.06	8.25	4.29
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	73.40	40.48	95.71	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	99.31	55.03	267.37	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	100.39	5.43	2,098.11	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	53.66	39.42	89.19	0.00	54.77
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	102.65	70.29	0.00	0.00	5.92
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.10	1.25	0.80	0.74	2.52
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.25	0.80	0.00	2.52
Financial Leverage	-1.23	-1.15	-1.19	-0.99	-0.76	-0.69	-0.68	-0.88	-0.24	0.32	0.87
Leverage Ratio	1.48	1.48	1.89	2.19	1.96	1.60	1.96	3.12	2.76	2.42	3.15
Compound Leverage Factor	1.47	1.48	1.95	2.36	1.95	1.52	1.96	2.83	2.27	0.84	3.76
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.46%	55.50%	44.44%	42.64%	71.61%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.46%	0.00%	0.00%	42.64%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	55.50%	44.44%	0.00%	71.61%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	90.53%	44.50%	55.56%	57.36%	28.39%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	-0.59	5.79	6.69	10.94	-15.39
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	4.33	-4.36	0.63	7.91	-11.57
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.79	6.69	0.00	-15.39
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	-0.57	7.92	0.90	239.73	-11.75
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	4.16	-5.96	0.08	173.43	-8.83
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.92	0.90	0.00	-11.75
Altman Z-Score	0.00	0.00	0.00	0.00	-4.89	-2.77	-3.88	2.34	1.24	1.34	-1.01
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.86	2.16	1.42	1.43	1.79	2.22	1.34	2.93	2.38	0.52	1.47
Quick Ratio	3.55	1.92	1.12	0.87	1.22	1.72	1.01	2.66	1.94	0.26	0.78
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-27	-36	6.46	-24	-15	-12	3.05	17	-27	-103	101
Operating Cash Flow to CapEx	-3,742.25%	-398.13%	-445.95%	-1,079.93%	-685.26%	0.00%	152.86%	316.12%	16.78%	-16.35%	34.43%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	-1,057.22	380.75	15.02	-10.19	-34.09	23.38
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	-1,054.09	728.38	26.79	3.53	-4.22	2.53
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-641.00	251.88	18.31	-17.52	-30.04	-4.81
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.33	0.28	0.43	0.51	0.50	0.62	0.64	0.51	0.34	0.34	0.36
Accounts Receivable Turnover	14.96	10.41	13.30	10.87	9.33	9.63	7.47	6.99	6.07	7.69	8.01
Inventory Turnover	0.00	2.42	1.95	1.55	2.30	4.09	6.40	5.85	4.37	3.37	3.57
Fixed Asset Turnover	8.74	3.05	2.25	2.29	2.04	2.06	2.26	2.97	1.83	1.10	0.77
Accounts Payable Turnover	0.00	2.43	2.44	6.70	23.04	14.82	10.85	8.77	8.84	6.91	5.86
Days Sales Outstanding (DSO)	24.39	35.06	27.45	33.57	39.13	37.89	48.85	52.25	60.11	47.49	45.58
Days Inventory Outstanding (DIO)	0.00	150.79	187.06	235.10	158.88	89.27	57.07	62.39	83.46	108.41	102.24
Days Payable Outstanding (DPO)	0.00	150.03	149.51	54.52	15.84	24.64	33.63	41.63	41.28	52.83	62.30
Cash Conversion Cycle (CCC)	24.39	35.82	65.01	214.15	182.17	102.52	72.29	73.01	102.29	103.08	85.53
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-9.79	-8.97	-12	13	13	21	10	4.77	188	291	176
Invested Capital Turnover	-2.11	-2.86	-4.24	116.19	4.13	3.18	3.89	12.97	1.24	0.62	0.60
Increase / (Decrease) in Invested Capital	1.65	0.83	-2.97	25	0.09	7.69	-11	-5.24	183	103	-114
Enterprise Value (EV)	0.00	0.00	0.00	0.00	162	236	313	1,229	844	1,231	600
Market Capitalization	0.00	0.00	0.00	0.00	204	269	345	1,302	831	1,129	484
Book Value per Share	$0.38	$0.31	$0.21	$0.18	$1.00	$0.95	$0.74	$1.28	$2.83	$3.02	$0.96
Tangible Book Value per Share	$0.38	$0.31	$0.21	$0.18	$1.00	$0.95	$0.74	$1.28	$2.83	$3.02	$0.96
Total Capital	68	59	50	54	56	53	46	175	314	330	214
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	4.38	97	140	141	154
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	97	140	0.00	154
Net Debt	-77	-68	-61	-47	-42	-32	-32	-73	13	102	115
Capital Expenditures (CapEx)	0.76	9.05	8.88	3.63	3.79	-4.54	3.81	9.86	56	78	32
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-14	-25	-37	-20	-12	-4.20	-17	-33	-22	-0.96	-4.67
Debt-free Net Working Capital (DFNWC)	64	43	24	27	30	28	20	137	104	38	33
Net Working Capital (NWC)	64	43	24	27	30	28	15	137	104	-103	33
Net Nonoperating Expense (NNE)	10	15	59	29	7.37	0.28	2.81	1.03	28	0.33	128
Net Nonoperating Obligations (NNO)	-77	-68	-62	-41	-43	-32	-32	-73	13	102	116
Total Depreciation and Amortization (D&A)	0.99	1.04	1.54	2.46	2.56	2.75	3.09	4.37	5.51	8.26	13
Debt-free, Cash-free Net Working Capital to Revenue	-62.17%	-92.64%	-83.82%	-34.45%	-22.94%	-7.83%	-27.80%	-34.47%	-18.61%	-0.65%	-3.34%
Debt-free Net Working Capital to Revenue	283.76%	161.28%	54.63%	46.75%	55.88%	52.53%	32.93%	142.77%	87.18%	25.41%	23.90%
Net Working Capital to Revenue	283.76%	161.28%	54.63%	46.75%	55.88%	52.53%	25.60%	142.77%	87.18%	-68.80%	23.90%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.22)	($0.30)	($0.28)	($0.88)	($0.56)	($0.16)	($0.27)	$0.06	$2.08	$0.00	($2.23)
Adjusted Weighted Average Basic Shares Outstanding	179.21M	199.93M	241.46M	45.07M	55.79M	56.14M	56.51M	58.22M	61.48M	0.00	63.20M
Adjusted Diluted Earnings per Share	($0.22)	($0.30)	($0.28)	($0.88)	($0.56)	($0.16)	($0.27)	$0.06	$1.84	$0.00	($2.23)
Adjusted Weighted Average Diluted Shares Outstanding	179.21M	199.93M	241.46M	45.07M	55.79M	56.14M	56.51M	59.43M	70.47M	0.00	63.20M
Adjusted Basic & Diluted Earnings per Share	($0.22)	($0.30)	($0.28)	($0.88)	($0.56)	($0.16)	($0.27)	$0.06	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	161.58M	182.56M	216.27M	37.11M	47.06M	55.98M	56.33M	61.10M	61.83M	0.00	63.58M
Normalized Net Operating Profit after Tax (NOPAT)	-25	-35	2.44	0.90	-14	-3.94	-7.66	8.57	11	2.52	-13
Normalized NOPAT Margin	-111.58%	-131.99%	5.50%	1.57%	-25.30%	-7.34%	-12.83%	8.94%	9.03%	1.69%	-9.34%
Pre Tax Income Margin	-157.84%	-188.03%	8.11%	2.42%	-38.35%	-9.96%	-17.53%	11.70%	10.59%	1.07%	-19.25%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-511.09	-1,307.25	10.63	5.72	1.53	-5.21
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-357.76	-957.25	10.52	58.03	0.19	-3.01
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-98.00	-1,783.75	2.16	-15.32	-24.29	-12.54
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	55.33	-1,433.75	2.04	36.98	-25.63	-10.35
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-0.66%	-6.66%	-7.44%	-15.20%	-19.83%	-102.61%	-41.32%	39.73%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.66%	-6.66%	-7.44%	-15.20%	-19.83%	-102.61%	-41.32%	39.73%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Avid Bioservices' official financial filings.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-18.21%	19.31%	0.00%	20.66%	76.27%	2.82%	-26.94%	-11.06%	7.98%	6.49%	31.84%
EBITDA Growth	95.06%	-43.95%	-462.20%	25.48%	-65.02%	-76.63%	-1,638.70%	-157.98%	-99.20%	-95.48%	-23.51%
EBIT Growth	156.06%	-60.25%	0.00%	6.20%	-84.74%	-168.40%	-336.47%	-296.29%	-383.35%	-61.68%	-27.50%
NOPAT Growth	4,089.02%	-72.37%	0.00%	-108.17%	-100.39%	-179.07%	-318.11%	-948.26%	-78.09%	-13.55%	-12.56%
Net Income Growth	5,940.98%	-78.41%	55.02%	-110.99%	-100.28%	-255.91%	-1,730.96%	-2,331.58%	-36,647.46%	-160.79%	-82.82%
EPS Growth	8,700.00%	-80.00%	50.00%	-100.00%	-100.58%	-250.00%	-1,400.00%	0.00%	-19,500.00%	-200.00%	-80.00%
Operating Cash Flow Growth	-96.57%	26.69%	-109.79%	-233.69%	413.89%	95.36%	262.73%	153.12%	-60.03%	-1,459.32%	-36.03%
Free Cash Flow Firm Growth	-741.70%	-757.56%	204.29%	-681.15%	-94.20%	47.89%	-224.28%	87.35%	209.37%	220.30%	139.44%
Invested Capital Growth	3,832.64%	0.00%	0.00%	478.78%	55.07%	50.88%	0.00%	9.42%	-39.34%	-41.72%	-43.51%
Revenue Q/Q Growth	-28.34%	62.51%	-5.27%	9.38%	4.68%	-5.21%	-32.69%	33.16%	27.09%	-6.52%	-16.66%
EBITDA Q/Q Growth	125.83%	-51.67%	-109.92%	1,258.48%	-37.04%	-67.72%	-838.50%	61.37%	100.87%	81.48%	-20,259.18%
EBIT Q/Q Growth	166.59%	-64.78%	-191.17%	224.06%	-61.68%	-257.83%	-481.73%	44.21%	44.69%	9.94%	-358.77%
NOPAT Q/Q Growth	3,857.08%	-98.52%	-198.12%	85.79%	-90.46%	-197.69%	-418.82%	64.36%	67.64%	-89.80%	-414.29%
Net Income Q/Q Growth	5,250.36%	-98.87%	-138.21%	52.50%	-35.63%	-533.43%	-348.68%	36.92%	-1,949.68%	95.50%	-214.53%
EPS Q/Q Growth	4,200.00%	-98.84%	-150.00%	100.00%	0.00%	-200.00%	-400.00%	40.00%	-2,077.78%	95.41%	-200.00%
Operating Cash Flow Q/Q Growth	-88.21%	-931.54%	24.60%	-80.90%	145.31%	-107.50%	2,745.76%	-40.95%	-65.91%	-392.76%	208.53%
Free Cash Flow Firm Q/Q Growth	-89.67%	-277.45%	219.99%	-190.94%	52.85%	-1.28%	-186.19%	90.75%	507.79%	11.40%	-6.17%
Invested Capital Q/Q Growth	308.41%	8.59%	-100.00%	0.00%	9.43%	5.65%	-4.64%	-0.74%	-39.34%	1.52%	-7.58%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	53.25%	24.85%	11.93%	25.84%	21.08%	10.87%	-18.37%	7.05%	12.80%	14.22%	-6.11%
EBITDA Margin	42.48%	12.63%	-1.32%	14.02%	8.43%	2.87%	-31.49%	-9.14%	0.06%	0.12%	-29.50%
Operating Margin	35.02%	7.45%	-7.72%	7.15%	2.09%	-5.73%	-44.19%	-11.83%	-3.01%	-6.11%	-37.72%
EBIT Margin	35.02%	7.59%	-7.31%	8.29%	3.03%	-5.05%	-43.64%	-18.28%	-7.96%	-7.67%	-42.20%
Profit (Net Income) Margin	532.71%	3.71%	-1.50%	-0.65%	-0.84%	-5.62%	-37.49%	-17.76%	-286.45%	-13.78%	-51.99%
Tax Burden Percent	1,636.19%	70.01%	15.22%	-9.83%	-61.13%	77.73%	79.95%	85.09%	2,353.81%	100.00%	100.00%
Interest Burden Percent	92.97%	69.80%	134.54%	79.81%	45.40%	143.31%	107.46%	114.15%	152.92%	179.68%	123.18%
Effective Tax Rate	-1,536.19%	29.99%	0.00%	109.83%	161.13%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	712.44%	6.43%	0.00%	-0.60%	-0.80%	-2.36%	-29.75%	-4.07%	-1.26%	-2.50%	-17.33%
ROIC Less NNEP Spread (ROIC-NNEP)	742.75%	1.95%	0.00%	-0.54%	-0.49%	-3.22%	-32.79%	-7.42%	-113.74%	-5.72%	-24.76%
Return on Net Nonoperating Assets (RNNOA)	-176.38%	0.27%	0.00%	-0.16%	-0.16%	-1.24%	-19.62%	-3.88%	-98.83%	-5.46%	-25.01%
Return on Equity (ROE)	536.05%	6.70%	0.00%	-0.75%	-0.95%	-3.60%	-49.38%	-7.95%	-100.09%	-7.96%	-42.34%
Cash Return on Invested Capital (CROIC)	-28.39%	-37.04%	0.00%	-42.45%	-42.94%	-40.91%	-204.70%	-13.16%	43.38%	47.25%	49.39%
Operating Return on Assets (OROA)	12.05%	2.11%	0.00%	2.86%	1.03%	-1.70%	-13.50%	-5.52%	-2.83%	-2.81%	-16.30%
Return on Assets (ROA)	183.25%	1.03%	0.00%	-0.22%	-0.29%	-1.89%	-11.60%	-5.36%	-101.71%	-5.04%	-20.08%
Return on Common Equity (ROCE)	536.05%	6.70%	0.00%	-0.75%	-0.95%	-3.60%	-49.38%	-7.95%	-100.09%	-7.96%	-42.34%
Return on Equity Simple (ROE_SIMPLE)	0.00%	68.56%	0.00%	65.20%	0.00%	-1.69%	-6.67%	-9.98%	0.00%	-245.86%	-339.34%
Net Operating Profit after Tax (NOPAT)	129	1.91	-1.88	-0.27	-0.51	-1.51	-7.86	-2.80	-0.91	-1.72	-8.84
NOPAT Margin	572.93%	5.22%	-5.41%	-0.70%	-1.28%	-4.01%	-30.93%	-8.28%	-2.11%	-4.28%	-26.41%
Net Nonoperating Expense Percent (NNEP)	-30.32%	4.48%	0.00%	-0.06%	-0.30%	0.86%	3.04%	3.36%	112.47%	3.21%	7.43%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-2.42%	-	-	-	-4.44%
Cost of Revenue to Revenue	46.75%	75.15%	88.07%	74.16%	78.92%	89.13%	118.37%	92.95%	87.20%	85.78%	106.11%
SG&A Expenses to Revenue	18.23%	17.39%	19.65%	18.69%	18.99%	16.60%	25.82%	18.87%	15.81%	20.33%	31.62%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	18.23%	17.39%	19.65%	18.69%	18.99%	16.60%	25.82%	18.87%	15.81%	20.33%	31.62%
Earnings before Interest and Taxes (EBIT)	7.91	2.79	-2.54	3.15	1.21	-1.91	-11	-6.18	-3.42	-3.08	-14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	9.59	4.64	-0.46	5.33	3.36	1.08	-8.00	-3.09	0.03	0.05	-9.88
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.76	6.79	0.00	5.32	5.97	4.17	2.12	2.38	7.95	11.32	14.18
Price to Tangible Book Value (P/TBV)	4.76	6.79	0.00	5.32	5.97	4.17	2.12	2.38	7.95	11.32	14.18
Price to Revenue (P/Rev)	6.95	9.68	8.39	7.47	7.56	5.28	2.75	3.13	3.46	4.66	4.22
Price to Earnings (P/E)	6.51	9.90	8.54	8.16	4,358.97	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	15.36%	10.10%	11.71%	12.25%	0.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.50	6.09	0.00	4.01	4.23	2.96	1.70	1.85	3.40	4.38	4.57
Enterprise Value to Revenue (EV/Rev)	7.06	9.88	0.00	8.08	8.25	6.06	3.53	3.94	4.29	5.51	5.03
Enterprise Value to EBITDA (EV/EBITDA)	40.48	72.01	0.00	55.87	95.71	97.91	281.44	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	55.03	111.50	0.00	94.38	267.37	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	5.43	7.47	0.00	6.94	2,098.11	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	89.19	109.54	0.00	0.00	0.00	0.00	225.08	41.97	54.77	104.46	143.81
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.92	6.82	6.68
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.80	0.78	0.00	0.76	0.74	0.75	0.77	0.78	2.52	2.62	3.44
Long-Term Debt to Equity	0.80	0.78	0.00	0.76	0.00	0.01	0.00	0.00	2.52	2.62	3.44
Financial Leverage	-0.24	0.14	0.00	0.29	0.32	0.38	0.60	0.52	0.87	0.95	1.01
Leverage Ratio	2.76	2.52	0.00	3.16	2.42	2.42	2.48	2.48	3.15	3.12	3.41
Compound Leverage Factor	2.56	1.76	0.00	2.52	1.10	3.47	2.67	2.83	4.82	5.61	4.21
Debt to Total Capital	44.44%	43.86%	0.00%	43.09%	42.64%	42.79%	43.50%	43.98%	71.61%	72.41%	77.48%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	42.64%	42.36%	43.50%	43.98%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	44.44%	43.86%	0.00%	43.09%	0.00%	0.43%	0.00%	0.00%	71.61%	72.41%	77.48%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	55.56%	56.14%	0.00%	56.91%	57.36%	57.21%	56.50%	56.02%	28.39%	27.59%	22.52%
Debt to EBITDA	6.69	8.12	0.00	7.35	10.94	15.29	79.79	-21.27	-15.39	-13.97	-11.96
Net Debt to EBITDA	0.63	1.43	0.00	4.21	7.91	12.58	62.03	-16.65	-11.57	-10.94	-9.36
Long-Term Debt to EBITDA	6.69	8.12	0.00	7.35	0.00	0.15	0.00	0.00	-15.39	-13.97	-11.96
Debt to NOPAT	0.90	0.84	0.00	0.91	239.73	-156.75	-20.50	-12.21	-11.75	-11.59	-10.81
Net Debt to NOPAT	0.08	0.15	0.00	0.52	173.43	-128.94	-15.94	-9.56	-8.83	-9.07	-8.46
Long-Term Debt to NOPAT	0.90	0.84	0.00	0.91	0.00	-1.57	0.00	0.00	-11.75	-11.59	-10.81
Altman Z-Score	1.18	1.88	0.00	1.33	1.31	0.55	-0.58	-0.51	-0.82	-0.46	-0.80
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.38	1.94	0.00	1.52	0.52	0.48	0.48	0.46	1.47	1.46	1.30
Quick Ratio	1.94	1.51	0.00	0.86	0.26	0.20	0.20	0.22	0.78	0.76	0.70
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-53	-202	242	-220	-104	-105	-301	-28	114	126	119
Operating Cash Flow to CapEx	2.49%	-74.09%	-11.15%	-61.41%	12.47%	-1.67%	83.61%	82.15%	22.08%	-280.70%	115.87%
Free Cash Flow to Firm to Interest Expense	-96.15	-239.93	276.08	-346.19	-157.54	-127.45	-363.87	-31.82	62.73	51.54	36.23
Operating Cash Flow to Interest Expense	1.10	-6.05	-4.38	-10.91	4.77	-0.29	7.55	4.21	0.69	-1.50	1.22
Operating Cash Flow Less CapEx to Interest Expense	-43.08	-14.22	-43.61	-28.69	-33.50	-17.44	-1.48	-0.92	-2.45	-2.03	0.17
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.28	0.00	0.35	0.34	0.34	0.31	0.30	0.36	0.37	0.39
Accounts Receivable Turnover	6.07	4.84	0.00	6.17	7.69	7.13	10.53	8.20	8.01	7.66	9.46
Inventory Turnover	4.37	3.00	0.00	2.93	3.37	3.48	3.20	3.18	3.57	3.81	4.17
Fixed Asset Turnover	1.83	1.09	0.00	1.13	1.10	1.01	0.75	0.78	0.77	0.77	0.81
Accounts Payable Turnover	8.84	2.99	0.00	4.52	6.91	4.65	5.41	4.53	5.86	6.23	8.67
Days Sales Outstanding (DSO)	60.11	75.44	0.00	59.20	47.49	51.19	34.65	44.53	45.58	47.65	38.56
Days Inventory Outstanding (DIO)	83.46	121.53	0.00	124.55	108.41	104.96	114.23	114.92	102.24	95.83	87.58
Days Payable Outstanding (DPO)	41.28	121.96	0.00	80.67	52.83	78.51	67.45	80.64	62.30	58.56	42.09
Cash Conversion Cycle (CCC)	102.29	75.01	0.00	103.09	103.08	77.63	81.42	78.81	85.53	84.92	84.05
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	188	204	0.00	266	291	307	293	291	176	179	166
Invested Capital Turnover	1.24	1.23	0.00	0.85	0.62	0.59	0.96	0.49	0.60	0.59	0.66
Increase / (Decrease) in Invested Capital	183	204	-244	220	103	104	293	25	-114	-128	-128
Enterprise Value (EV)	844	1,240	0.00	1,067	1,231	911	498	539	600	784	756
Market Capitalization	831	1,215	1,053	986	1,129	794	388	428	484	664	635
Book Value per Share	$2.83	$2.89	$0.00	$2.98	$3.02	$3.03	$2.90	$2.85	$0.96	$0.92	$0.70
Tangible Book Value per Share	$2.83	$2.89	$0.00	$2.98	$3.02	$3.03	$2.90	$2.85	$0.96	$0.92	$0.70
Total Capital	314	319	0.00	326	330	333	324	322	214	213	199
Total Debt	140	140	0.00	140	141	142	141	141	154	154	154
Total Long-Term Debt	140	140	0.00	140	0.00	1.42	0.00	0.00	154	154	154
Net Debt	13	25	0.00	80	102	117	110	111	115	120	121
Capital Expenditures (CapEx)	25	6.87	34	11	25	14	7.47	4.49	5.69	1.31	3.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-22	-28	0.00	-15	-0.96	8.02	-5.34	-8.59	-4.67	-0.84	-11
Debt-free Net Working Capital (DFNWC)	104	87	0.00	45	38	33	26	22	33	33	22
Net Working Capital (NWC)	104	87	0.00	45	-103	-108	-115	-119	33	33	22
Net Nonoperating Expense (NNE)	9.08	0.55	-1.36	-0.02	-0.17	0.61	1.67	3.21	122	3.81	8.56
Net Nonoperating Obligations (NNO)	13	25	0.00	80	102	117	110	111	116	120	121
Total Depreciation and Amortization (D&A)	1.68	1.85	2.08	2.18	2.15	2.99	3.08	3.09	3.45	3.13	4.25
Debt-free, Cash-free Net Working Capital to Revenue	-18.61%	-22.18%	0.00%	-11.28%	-0.65%	5.33%	-3.79%	-6.28%	-3.34%	-0.59%	-7.36%
Debt-free Net Working Capital to Revenue	87.18%	69.54%	0.00%	34.10%	25.41%	22.13%	18.51%	16.18%	23.90%	22.86%	14.86%
Net Working Capital to Revenue	87.18%	69.54%	0.00%	34.10%	-68.80%	-71.61%	-81.65%	-87.25%	23.90%	22.86%	14.86%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.96	$0.03	$0.00	$0.01	($0.01)	$0.00	$0.00	($0.09)	($1.96)	($0.09)	($0.27)
Adjusted Weighted Average Basic Shares Outstanding	61.48M	61.91M	0.00	62.39M	62.27M	0.00	0.00	63.32M	63.20M	63.64M	63.84M
Adjusted Diluted Earnings per Share	$1.72	$0.02	$0.00	$0.01	($0.01)	$0.00	$0.00	($0.09)	($1.96)	($0.09)	($0.27)
Adjusted Weighted Average Diluted Shares Outstanding	70.47M	63.33M	0.00	63.73M	63.78M	0.00	0.00	63.32M	63.20M	63.64M	63.84M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	61.83M	62.17M	0.00	62.55M	62.73M	0.00	0.00	63.48M	63.58M	63.80M	63.96M
Normalized Net Operating Profit after Tax (NOPAT)	5.53	1.91	-1.88	1.90	0.58	-1.51	-7.86	-2.80	-0.91	-1.72	-8.84
Normalized NOPAT Margin	24.51%	5.22%	-5.41%	5.00%	1.46%	-4.01%	-30.93%	-8.28%	-2.11%	-4.28%	-26.41%
Pre Tax Income Margin	32.56%	5.30%	-9.83%	6.61%	1.38%	-7.24%	-46.90%	-20.87%	-12.17%	-13.78%	-51.99%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	14.22	3.31	-2.90	4.95	1.83	-2.31	-13.40	-7.07	-1.89	-1.26	-4.31
NOPAT to Interest Expense	232.66	2.28	-2.14	-0.42	-0.77	-1.84	-9.50	-3.20	-0.50	-0.70	-2.70
EBIT Less CapEx to Interest Expense	-29.96	-4.86	-42.13	-12.82	-36.44	-19.47	-22.43	-12.20	-5.03	-1.79	-5.37
NOPAT Less CapEx to Interest Expense	188.47	-5.89	-41.38	-18.19	-39.05	-18.99	-18.53	-8.33	-3.65	-1.23	-3.75
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Avid Bioservices' Financials

When does Avid Bioservices's fiscal year end?

According to the most recent income statement we have on file, Avid Bioservices' financial year ends in April. Their financial year 2024 ended on April 30, 2024.

How has Avid Bioservices' net income changed over the last 10 years?

Avid Bioservices' net income appears to be on a downward trend, with a most recent value of -$140.75 million in 2024, rising from -$35.36 million in 2014. The previous period was $259 thousand in 2023.

What is Avid Bioservices's operating income?

Avid Bioservices's total operating income in 2024 was -$18.68 million, based on the following breakdown:

Total Gross Profit: $7.32 million
Total Operating Expenses: $26.00 million

How has Avid Bioservices revenue changed over the last 10 years?

Over the last 10 years, Avid Bioservices' total revenue changed from $22.40 million in 2014 to $139.91 million in 2024, a change of 524.6%.

How much debt does Avid Bioservices have?

Avid Bioservices' total liabilities were at $275.67 million at the end of 2024, a 5.1% increase from 2023, and a 1,106.6% increase since 2014.

How much cash does Avid Bioservices have?

In the past 10 years, Avid Bioservices' cash and equivalents has ranged from $32.35 million in 2019 to $169.92 million in 2021, and is currently $38.11 million as of their latest financial filing in 2024.

How has Avid Bioservices' book value per share changed over the last 10 years?

Over the last 10 years, Avid Bioservices' book value per share changed from 0.38 in 2014 to 0.96 in 2024, a change of 150.1%.

Remove Ads

Related Companies

This page (NASDAQ:CDMO) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avid Bioservices (CDMO) Financials

Frequently Asked Questions About Avid Bioservices' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avid Bioservices (CDMO) Financials

Annual Income Statements for Avid Bioservices

Quarterly Income Statements for Avid Bioservices

Annual Cash Flow Statements for Avid Bioservices

Quarterly Cash Flow Statements for Avid Bioservices

Annual Balance Sheets for Avid Bioservices

Quarterly Balance Sheets for Avid Bioservices

Annual Metrics and Ratios for Avid Bioservices

Quarterly Metrics and Ratios for Avid Bioservices

Frequently Asked Questions About Avid Bioservices' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools